| JDMAX | NBMBX | JDMAX / NBMBX | |
| Total Expense Ratio | 1.14 | 1.18 | 97% |
| Annual Report Gross Expense Ratio | 1.14 | 1.18 | 97% |
| Fund Existence | 17 years | 30 years | - |
| Gain YTD | 9.308 | 4.101 | 227% |
| Front Load | 6% | N/A | - |
| Min. Initial Investment | 2500 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 21.8B | 2.23B | 977% |
| Annual Yield % from dividends | 0.00 | 0.00 | - |
| Returns for 1 year | 4.44 | -18.65 | -24% |
| Returns for 3 years | 16.98 | 7.83 | 217% |
| Returns for 5 years | -13.55 | -32.05 | 42% |
| Returns for 10 years | 56.06 | 12.40 | 452% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SPXX | 19.08 | 0.09 | +0.47% |
| Nuveen S&P 500 Dynamic Overwrite Fund | |||
| FBDC | 17.67 | N/A | -0.01% |
| FT Confluence BDC & SpecialtyFinacIncETF | |||
| CALI | 50.38 | -0.01 | -0.03% |
| iShares Short-Term CA Muni Act ETF | |||
| WEA | 10.43 | -0.05 | -0.48% |
| Western Asset Premier | |||
| BIS | 10.82 | -0.30 | -2.70% |
| ProShares UltraShort Nasdaq Biotech | |||